AMPH - Amphastar Pharmaceuticals Inc

NYSE * Health Care * Pharmaceuticals

$20.44

+$0.48 (+2.40%)

About Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

AMPH Key Statistics

Market Cap

$928.04M

P/E Ratio

9.83

P/B Ratio

1.15

EPS

$2.03

Revenue Growth

-0.0%

Profit Margin

0.1%

Employees

1,976

How AMPH Compares to Peers

AMPH has the lowest P/E ratio in Pharmaceuticals, suggesting it may be the most undervalued
AMPH has the highest profit margins in Pharmaceuticals
AMPH is the smallest among peers, which may offer higher growth potential

P/E Rank

#1

of 2

Margin Rank

#1

of 2

Growth Rank

#2

of 2

Size Rank

#2

of 2

CompanyP/EGrowthCompare
AMPH9.8-0%-
AMZN30.20%vs AMZN

Amphastar Pharmaceuticals Inc Company Information

Headquarters
California; U.S.A
Website
www.amphastar.com
Sector
Health Care
Industry
Pharmaceuticals
Data Updated:
Ready to invest in AMPH?

Commission-free trading available. Affiliate links.

AMPH Lician Score

10% confidence
5.0/10
Neutral

AMPH has a Lician Score of 5/10 (Average). The stock shows average characteristics across all dimensions.

value

5.0

growth

4.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates AMPHacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

AMPH Financial Snowflake

5-axis analysis across key investment dimensions

4.8/10

Neutral

35810Value5.0Growth4.0Quality5.0Momentum5.0Safety5.04.8/10
5.0

Value

4.0

Growth

5.0

Quality

5.0

Momentum

5.0

Safety

Upcoming Events for AMPH